查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1471954

肺給藥系統市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按產品、適應症、配銷通路、最終用戶和地理位置

Pulmonary Drug Delivery Systems Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Indication, Distribution Channel, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

肺部給藥系統市場規模預計將從2023年的497.1億美元成長到2031年的731.4億美元；預計 2023 年至 2031 年市場複合年成長率為 4.9%。

肺部給藥是指將藥物直接輸送到肺部的技術和方法。這些系統旨在透過吸入將氣溶膠直接輸送至上皮細胞和呼吸道上皮。這些系統利用肺部的大表面積、薄上皮層和豐富的血液供應來促進藥物的快速有效吸收。肺部給藥系統市場的成長歸因於呼吸系統疾病負擔的增加和公司不斷增加的策略性舉措。然而，與肺部藥物輸送系統的批准相關的監管問題阻礙了肺部藥物輸送系統市場的成長。

最近，已採取各種措施和措施來提高人們對呼吸系統疾病的認知並進行教育，促使患者獲得適合此類疾病的藥物和治療。 Cipla 為慢性氣道疾病患者開展了一項名為「Breathefree」的公共服務計劃。 Berok Zindagi 的計畫旨在讓氣喘患者發揮真正的潛力，並透過使用吸入器過著不可阻擋的生活。 Berok Zindagi 被精心設計為一種工具，為消費者提供他們所需的所有資訊，讓他們毫不猶豫地使用吸入器，並直面與吸入療法相關的恥辱。透過使用多語言和多媒體教育資源來提高對疾病和吸入器的認知，教育工作者確保為患者提供諮詢。透過 600 多名 Breathefree 教育工作者和 5,600 多名醫生的努力，Breathefree Clinic 服務為印度各地超過 1,25,000 多名呼吸系統患者提供服務。

疾病預防控制中心的國家氣喘控制計劃也提供資金，用於教育氣喘患者接受有關其病情的教育。因此，此類措施可能會提高人們對呼吸系統疾病的認知，為肺部給藥系統市場的成長提供新的機會。

基於配銷通路的見解

根據配銷通路，肺部給藥系統市場分為醫院藥房、零售藥房和電子商務。到 2023 年，醫院藥局細分市場將佔據重要的肺部給藥系統市場。醫院藥局是整合到醫院、診所、毒物控制中心、住宿護理機構的藥物資訊中心和藥物依賴設施中心等醫療保健中心的專業藥局。這些藥房提供的主要好處是支援大量庫存的儲存、現場提供各種藥品以及對醫療保健計劃下購買的藥品進行報銷。醫院藥局不是零售場所；他們通常為住院患者提供藥物。因此，他們不向公眾提供處方服務。因此，專業治療藥物的容易取得有助於患者傾向於醫院藥房，這對肺部藥物輸送系統市場的成長有正面影響。

基於最終用戶的見解

根據最終用戶，肺部給藥系統市場分為醫院和診所以及家庭護理。 2023 年，醫院和診所部門在肺部給藥系統市場中佔有重要佔有率。

美國食品藥物管理局、世界衛生組織和疾病管制與預防中心是在準備肺部藥物輸送系統市場報告時提到的主要和次要來源之一。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解
  • 市場吸引力分析

第 3 章：研究方法

第 4 章：肺部給藥系統市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈供應商名單

第 5 章：肺部給藥系統市場 - 主要市場動態

  • 主要市場促進因素
  • 主要市場限制
  • 主要市場機會
  • 未來的趨勢
  • 促進因素和限制因素的影響分析

第 6 章：肺部給藥系統市場 - 全球市場分析

  • 肺部給藥系統 - 全球市場概覽
  • 肺部給藥系統 - 全球市場與 2031 年預測

第 7 章：肺部給藥系統市場 - 收入分析 - 按產品，2021-2031 年

  • 概述
  • 乾粉吸入器
  • 定量吸入器
  • 霧化器

第 8 章：肺部給藥系統市場 - 收入分析 - 按適應症分類，2021-2031 年

  • 概述
  • 慢性阻塞性肺臟疾病
  • 氣喘
  • 囊腫纖維化
  • 其他

第 9 章：肺部給藥系統市場 - 收入分析 - 按配銷通路，2021-2031 年

  • 概述
  • 醫院藥房
  • 零售藥局
  • 電子商務

第 10 章：肺部給藥系統市場 - 收入分析 - 按最終用戶，2021-2031 年

  • 概述
  • 醫院和診所
  • 居家護理

第 11 章：肺部給藥系統市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

註 - 將為以下提到的地區/國家提供類似的分析

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第13章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與專注

第 14 章：肺部給藥系統市場 - 主要公司概況

  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Koninklijke Philips NV
  • Cipla Inc.
  • OMRON Corp.
  • PARI GmbH
  • Glenmark Pharmaceuticals
  • Gilbert Technologies

第 15 章：附錄

簡介目錄
Product Code: TIPHE100001256

The pulmonary drug delivery systems market size is expected to grow from US$ 49.71 billion in 2023 to US$ 73.14 billion by 2031; the market is projected to register a CAGR of 4.9% during 2023-2031.

Pulmonary drug delivery refers to the technologies and methods used to deliver medications directly into the lungs. These systems are aimed at targeting the delivery of aerosols directly to epithelial cells and respiratory epithelium by means of inhalation. These systems take advantage of the lung's large surface area, thin epithelial layer, and rich blood supply to facilitate rapid and efficient absorption of medications. The pulmonary drug delivery systems market growth is attributed to the increasing burden of respiratory diseases and growing strategic initiatives by companies. However, regulatory issues associated with the approval of pulmonary drug delivery systems hinder the growth of the pulmonary drug delivery systems market.

Recently, various initiatives and measures have been taken to create awareness and educate people regarding respiratory diseases, prompting patients to access suitable medications and treatments for such conditions. Cipla has a public service initiative called Breathefree for people with chronic airway diseases. Berok Zindagi's program seeks to enable asthmatics to reach their true potential and lead lives that are unstoppable with the use of an inhaler. Berok Zindagi has been crafted as a tool to arm consumers with all the information they require to embrace inhalers without reluctance and confront the stigma associated with inhalation therapy. By using multilingual and multimedia educational resources to raise awareness about illnesses and inhalers, educators ensure patient counseling. Through the efforts of 600+ Breathefree Educators and 5600+ doctors, the Breathefree Clinic service serves over 1,25,000+ respiratory patients throughout India.

CDC's National Asthma Control Program also provides funds for educating patients with asthma to receive education regarding their condition. Thus, such initiatives are likely to increase awareness about respiratory diseases, offering new opportunities for the growth of the pulmonary drug delivery systems market.

Distribution Channel-Based Insights

Based on distribution channel, the pulmonary drug delivery systems market is categorized into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held a significant pulmonary drug delivery systems market share in 2023. In addition, the e-commerce segment is expected to register the highest CAGR during the forecast period. Hospital pharmacies are specialized pharmacies integrated into healthcare centers such as hospitals, clinics, poison control centers, residential care facilities' drug information centers, and drug dependency facility centers. Capacities to support the storage of extensive stocks, availability of various medicines on the spot, and reimbursement on the drugs purchased under healthcare plans are the primary benefits conferred by these pharmacies. Hospital pharmacies are not retail establishments; they typically provide medications for hospitalized patients. Therefore, they don't provide prescription services to the public. Hence, the ease of availability of specialized therapeutics contributes to the inclination of patients toward hospital pharmacies, which is positively influencing the pulmonary drug delivery systems market growth.

End User-Based Insights

Based on end user, the pulmonary drug delivery systems market is categorized into hospitals & clinics and homecare. The hospitals & clinics segment held a significant pulmonary drug delivery systems market share in 2023. The homecare segment is estimated to register a higher CAGR during 2023-2031.

The US Food and Drug Administration, the World Health Organization, and the Centers for Disease Control and Prevention are among the primary and secondary sources referred to while preparing the pulmonary drug delivery systems market report.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Pulmonary Drug Delivery Systems Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Pulmonary Drug Delivery Systems Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Pulmonary Drug Delivery Systems Market - Global Market Analysis

  • 6.1 Pulmonary Drug Delivery Systems - Global Market Overview
  • 6.2 Pulmonary Drug Delivery Systems - Global Market and Forecast to 2031

7. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Product, 2021-2031

  • 7.1 Overview
  • 7.2 Dry Powder Inhalers
  • 7.3 Metered Dose Inhalers
  • 7.4 Nebulizers

8. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Chronic Obstructive Pulmonary Disease
  • 8.3 Asthma
  • 8.4 Cystic Fibrosis
  • 8.5 Others

9. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 E-commerce

10. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals and Clinics
  • 10.3 Homecare

11. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Pulmonary Drug Delivery Systems Market Overview
    • 11.1.2 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts to 2031
    • 11.1.3 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Product
    • 11.1.4 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Indication
    • 11.1.5 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.6 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
    • 11.1.7 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Pulmonary Drug Delivery Systems Market
        • 11.1.7.1.1 United States Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.1.2 United States Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.1.3 United States Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.1.4 United States Pulmonary Drug Delivery Systems Market, by End User
      • 11.1.7.2 Canada Pulmonary Drug Delivery Systems Market
        • 11.1.7.2.1 Canada Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.2.2 Canada Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.2.3 Canada Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.2.4 Canada Pulmonary Drug Delivery Systems Market, by End User
      • 11.1.7.3 Mexico Pulmonary Drug Delivery Systems Market
        • 11.1.7.3.1 Mexico Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.3.2 Mexico Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.3.3 Mexico Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.3.4 Mexico Pulmonary Drug Delivery Systems Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Pulmonary Drug Delivery Systems Market - Key Company Profiles

  • 14.1 AstraZeneca plc
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 14.2 Boehringer Ingelheim International GmbH
  • 14.3 GlaxoSmithKline plc
  • 14.4 Novartis AG
  • 14.5 Koninklijke Philips NV
  • 14.6 Cipla Inc.
  • 14.7 OMRON Corp.
  • 14.8 PARI GmbH
  • 14.9 Glenmark Pharmaceuticals
  • 14.10 Gilbert Technologies

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud